"At atai, we believe that collaborations and partnerships are key to driving innovation. We helped launch the atai Research Fellowship at Massachusetts General Hospital’s Center for the Neuroscience of Psychedelics to facilitate further research to address unmet patient needs in mental health. This fellowship provides graduate students with state-of-the-art resources, allowing them to pursue cutting-edge research in neuroscience. "
Tapped 1 billion market cap today. Atai is moving to the US and once the stock hits 5.00 that is when institutions usually buy in and they get added to indexes. The stars are aligning.
The Giglamesh buyout at $1.2B is just the first domino to fall in what will likely be a wave of consolidation in the psychedelic and CNS biotech space. This isn’t just a headline number — it’s a signal that large pharma is finally willing to put serious capital behind these assets. A $1.2B exit validates the entire sector and proves that late-stage psychedelic biotechs are no longer just speculative stories — they are strategic acquisition targets. This kind of transaction sets a clear benchmark for companies like MindMed and ATAI, both of which are advancing late-stage trials with massive addressable markets in depression, anxiety, addiction, and beyond. With big pharma under constant pressure to replenish pipelines and find differentiated therapies, deals of this size will only fuel competitive bidding. Investors should expect multiples to expand, valuations to rise, and M&A momentum to accelerate as these late-stage players approach key readouts. The Giglamesh deal is not an isolated event — it’s the start of a broader recognition that these treatments could redefine mental health, and the companies leading the charge are about to become prime takeover candidates.
BioSpace Podcast - Lilly’s Obesity Pill Heads to the FDA, AbbVie Bets on Psychedelics, HHS Unveils More Change https://open.spotify.com/episode/0yOpXdwETKEGtBfaKR8yFs?si=GSCsXz8rRsS5hPLqJ60YWw Keep these stocks on your watch list M&A is around the corner.
atai Life Sciences Awarded Grant from the National Institutes of Health 5-year UG3/UH3 grant will fund the optimization and early-stage development of atai’s novel 5-HT2A/2C receptor agonists with non-hallucinogenic potential for opioid use disorder https://www.globenewswire.com/news-...t-from-the-National-Institutes-of-Health.html
$ATAI TD Cowen 5th Annual Novel Mechanisms in Neuropsychiatry & Epilepsy Summit https://wsw.com/webcast/cowen184/register.aspx?conf=cowen184&page=atai&url=https://wsw.com/webcast/cowen184/atai/1996519 Dr Srinivas Rao, ATAI CEO and Co-Founder, and Dr Kevin Craig, our Chief Medical Officer, joined Ritu Baral and Athena Chin at the T.D. Cowen Inc. 5th Annual Novel Mechanisms in Neuropsychiatry & Epilepsy Summit. The conversation spanned ATAI's latest research in treatment-resistant depression, their planned strategic combination with Beckley Psytech, and how they're bringing new treatment options to people who urgently need them. Listen to the replay to hear how atai is creating new possibilities for people living with serious mental health conditions.
